WO2005039574A8 - 角結膜障害の治療剤 - Google Patents

角結膜障害の治療剤

Info

Publication number
WO2005039574A8
WO2005039574A8 PCT/JP2004/016063 JP2004016063W WO2005039574A8 WO 2005039574 A8 WO2005039574 A8 WO 2005039574A8 JP 2004016063 W JP2004016063 W JP 2004016063W WO 2005039574 A8 WO2005039574 A8 WO 2005039574A8
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
corneal
benzoimidazol
ylmethoxy
thiazolidine
Prior art date
Application number
PCT/JP2004/016063
Other languages
English (en)
French (fr)
Other versions
WO2005039574A1 (ja
Inventor
Masatsugu Nakamura
Shin-Ichiro Hirai
Original Assignee
Santen Pharmaceutical Co Ltd
Masatsugu Nakamura
Shin-Ichiro Hirai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd, Masatsugu Nakamura, Shin-Ichiro Hirai filed Critical Santen Pharmaceutical Co Ltd
Priority to CN2004800309819A priority Critical patent/CN1870997B/zh
Priority to DK04793171.2T priority patent/DK1679074T3/da
Priority to PL04793171T priority patent/PL1679074T3/pl
Priority to CA2543452A priority patent/CA2543452C/en
Priority to DE602004030470T priority patent/DE602004030470D1/de
Priority to AT04793171T priority patent/ATE490771T1/de
Priority to EP04793171A priority patent/EP1679074B1/en
Priority to KR1020067009936A priority patent/KR101154175B1/ko
Priority to US10/576,719 priority patent/US7358255B2/en
Priority to SI200431607T priority patent/SI1679074T1/sl
Publication of WO2005039574A1 publication Critical patent/WO2005039574A1/ja
Publication of WO2005039574A8 publication Critical patent/WO2005039574A8/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/JP2004/016063 2003-10-24 2004-10-22 角結膜障害の治療剤 WO2005039574A1 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN2004800309819A CN1870997B (zh) 2003-10-24 2004-10-22 角膜结膜病变的治疗剂
DK04793171.2T DK1679074T3 (da) 2003-10-24 2004-10-22 Terapeutisk middel til keratoconjunktive forstyrrelser
PL04793171T PL1679074T3 (pl) 2003-10-24 2004-10-22 Środek terapeutyczny do leczenia chorób zapalnych rogówki i spojówki
CA2543452A CA2543452C (en) 2003-10-24 2004-10-22 Therapeutic agent for keratoconjunctival disorder
DE602004030470T DE602004030470D1 (de) 2003-10-24 2004-10-22 Therapeutisches mittel für keratokonjunktive erkrankungen
AT04793171T ATE490771T1 (de) 2003-10-24 2004-10-22 Therapeutisches mittel für keratokonjunktive erkrankungen
EP04793171A EP1679074B1 (en) 2003-10-24 2004-10-22 Therapeutic agent for keratoconjunctive disorder
KR1020067009936A KR101154175B1 (ko) 2003-10-24 2004-10-22 각결막 장해 치료제
US10/576,719 US7358255B2 (en) 2003-10-24 2004-10-22 Therapeutic agent for keratoconjunctival disorder
SI200431607T SI1679074T1 (sl) 2003-10-24 2004-10-22 Terapevtsko sredstvo za keratokonjuktivno motnjo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003364864 2003-10-24
JP2003-364864 2003-10-24

Publications (2)

Publication Number Publication Date
WO2005039574A1 WO2005039574A1 (ja) 2005-05-06
WO2005039574A8 true WO2005039574A8 (ja) 2005-06-23

Family

ID=34510137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/016063 WO2005039574A1 (ja) 2003-10-24 2004-10-22 角結膜障害の治療剤

Country Status (16)

Country Link
US (1) US7358255B2 (ja)
EP (1) EP1679074B1 (ja)
JP (1) JP4217832B2 (ja)
KR (1) KR101154175B1 (ja)
CN (1) CN1870997B (ja)
AT (1) ATE490771T1 (ja)
CA (1) CA2543452C (ja)
CY (1) CY1111191T1 (ja)
DE (1) DE602004030470D1 (ja)
DK (1) DK1679074T3 (ja)
ES (1) ES2357801T3 (ja)
PL (1) PL1679074T3 (ja)
PT (1) PT1679074E (ja)
SI (1) SI1679074T1 (ja)
TW (1) TWI343256B (ja)
WO (1) WO2005039574A1 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2543555A1 (en) * 2003-10-29 2005-05-06 Santen Pharmaceutical Co., Ltd. Therapeutic agent for keratoconjunctival disorder
WO2006064825A1 (ja) * 2004-12-14 2006-06-22 Santen Pharmaceutical Co., Ltd. ドライアイ治療剤
US8148389B2 (en) 2005-11-28 2012-04-03 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising PPAR agonist
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
BRPI0811612A2 (pt) 2007-05-21 2014-11-11 Senju Pharma Co Composições farmacêuticas que contêm agonista ppardelta
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
RU2484848C2 (ru) * 2008-02-25 2013-06-20 Сантен Фармасьютикал Ко., Лтд. Агент для усиления барьерной функции эпителия роговицы
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
KR101771401B1 (ko) * 2009-05-22 2017-08-25 인사이트 홀딩스 코포레이션 야누스 키나제 억제제로서 피라졸­４­일­피롤로［２,３­ｄ］피리미딘 및 피롤­３­일­피롤로［２,３­ｄ］피리미딘의 Ｎ­(헤테로)아릴­피롤리딘 유도체
CN106967070A (zh) * 2009-05-22 2017-07-21 因塞特控股公司 作为jak抑制剂的化合物
US9249145B2 (en) * 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SI3050882T1 (en) 2010-03-10 2018-06-29 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives, as inhibitors of JAK1
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
AR083933A1 (es) 2010-11-19 2013-04-10 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2721028B1 (en) 2011-06-20 2015-11-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CN113384546A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
KR102419714B1 (ko) 2013-08-07 2022-07-13 인사이트 코포레이션 Jak1 억제제용 지속 방출 복용 형태
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
MD3746429T2 (ro) 2018-01-30 2022-08-31 Incyte Corp Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
SG11202009441PA (en) 2018-03-30 2020-10-29 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3769066D1 (de) * 1986-08-28 1991-05-08 Sanwa Kagaku Kenkyusho Co Hydantoin-derivate zur behandlung von komplikationen bei diabetes.
JP3072227B2 (ja) * 1994-08-01 2000-07-31 株式会社クボタ 田植機の粉粒体供給装置
JP3603129B2 (ja) 1994-12-28 2004-12-22 株式会社三和化学研究所 糖尿病性角膜症の治療剤
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) * 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
WO1997041097A2 (en) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
JPH11130675A (ja) * 1997-08-29 1999-05-18 Santen Pharmaceut Co Ltd クロマン誘導体含有点眼液
EP0909558A3 (en) * 1997-08-29 1999-10-27 Santen Pharmaceutical Co., Ltd. Chroman derivative containing ophthalmic solution
JP2001039976A (ja) 1999-05-24 2001-02-13 Sankyo Co Ltd 縮合複素環化合物の塩酸塩
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
JP2002220336A (ja) 2000-11-22 2002-08-09 Sankyo Co Ltd 縮合複素環化合物の塩酸塩を含有する糖尿病の予防薬、治療薬
JP4090013B2 (ja) 2000-12-26 2008-05-28 第一三共株式会社 利尿剤及びインスリン抵抗性改善剤を含有する医薬組成物
CA2543555A1 (en) * 2003-10-29 2005-05-06 Santen Pharmaceutical Co., Ltd. Therapeutic agent for keratoconjunctival disorder

Also Published As

Publication number Publication date
WO2005039574A1 (ja) 2005-05-06
ES2357801T3 (es) 2011-04-29
US7358255B2 (en) 2008-04-15
CA2543452A1 (en) 2005-05-06
US20070060628A1 (en) 2007-03-15
TWI343256B (en) 2011-06-11
DE602004030470D1 (de) 2011-01-20
DK1679074T3 (da) 2011-03-21
CN1870997A (zh) 2006-11-29
JP2005145961A (ja) 2005-06-09
CY1111191T1 (el) 2015-06-11
KR101154175B1 (ko) 2012-06-14
TW200518750A (en) 2005-06-16
EP1679074A4 (en) 2009-03-25
CA2543452C (en) 2012-03-13
KR20060100440A (ko) 2006-09-20
PL1679074T3 (pl) 2011-05-31
EP1679074A1 (en) 2006-07-12
PT1679074E (pt) 2011-03-03
ATE490771T1 (de) 2010-12-15
CN1870997B (zh) 2011-05-04
SI1679074T1 (sl) 2011-04-29
EP1679074B1 (en) 2010-12-08
JP4217832B2 (ja) 2009-02-04

Similar Documents

Publication Publication Date Title
WO2005039574A8 (ja) 角結膜障害の治療剤
IL263314A (en) Use of Formula 2 receptor agonists for the treatment of ocular inflammatory diseases
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
HRP20090340T1 (en) 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases
HRP20141048T1 (hr) Spojevi, pripravci i metode
ZA200606880B (en) Diaminopyrimidines as P2X3 and P2X2/3 antagonists
WO2006124490A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
EP1078923A3 (en) Process for the preparation of benzothiophene derivatives
PE20081530A1 (es) Nuevos compuestos 617
PE20081532A1 (es) Compuestos novedosos
JP2006525364A5 (ja)
RU2008129723A (ru) Ингибиторы ccr9 активности
TW200700416A (en) 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites
US7589213B2 (en) Therapeutic substituted lactams
PE20070359A1 (es) Inhibidores de pirimidinilpirazol de aurora quinasas
EP1915998A8 (en) Prophylactic or therapeutic agent for corneal/conjunctival disease
TWI812944B (zh) 新穎苯基衍生物
RU2367659C2 (ru) Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar)
WO2009041565A1 (ja) キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤
AU2003238697A8 (en) Par-2-activating peptide derivative and pharmaceutical composition using the same
AU1916895A (en) Thiazolidinedione derivatives as anti-hyperglycemic agents
DE60212434D1 (de) Rosiglitazon-edisylate und ihre verwendung als antidiabetika
DK1315724T3 (da) Thiazolidindionderivat og dets anvendelse som antidiabetikum
CA2537410A1 (en) Ophthalmic indazole comprising compositions for treating ocular hypertension
EA200300005A1 (ru) Соль тиазолидиндиона для лечения сахарного диабета

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480030981.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007060628

Country of ref document: US

Ref document number: 2543452

Country of ref document: CA

Ref document number: 10576719

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004793171

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020067009936

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004793171

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067009936

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWP Wipo information: published in national office

Ref document number: 10576719

Country of ref document: US